<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Endemic Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (eBL) is the most common <z:e sem="disease" ids="C0278704" disease_type="Neoplastic Process" abbrv="">childhood cancer</z:e> in equatorial Africa and is linked to Epstein-Barr virus (EBV) and Plasmodium falciparum coinfections early in life </plain></SENT>
<SENT sid="1" pm="."><plain>Epstein-Barr nuclear antigen 1 (EBNA1) is the sole <z:mp ids='MP_0001799'>viral</z:mp> latent antigen expressed in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Loss of EBNA1-specific immune surveillance could allow eBL emergence </plain></SENT>
<SENT sid="3" pm="."><plain>Therefore, EBNA1-specific T cell responses were analyzed by IFN-gamma ELISPOT in Kenyan children with eBL and compared to healthy children with divergent <z:e sem="disease" ids="C0024530" disease_type="Disease or Syndrome" abbrv="">malaria</z:e> exposure </plain></SENT>
<SENT sid="4" pm="."><plain>Significantly fewer children with eBL, 16% (7/44) had EBNA1-specific IFN-gamma responses in contrast to healthy children living in a <z:e sem="disease" ids="C0024530" disease_type="Disease or Syndrome" abbrv="">malaria</z:e> holoendemic area or in an area with <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:e sem="disease" ids="C0024530" disease_type="Disease or Syndrome" abbrv="">malaria</z:e> transmission, 67% (40/60) and 72% (43/60) responders, respectively (p &lt; 0.003) </plain></SENT>
<SENT sid="5" pm="."><plain>Children with eBL maintained IgG(1) dominated antibody responses to EBNA1 similar to healthy children suggesting a selective loss of IFN-gamma secreting EBNA1-specific T cells in the presence of intact humoral immunity </plain></SENT>
<SENT sid="6" pm="."><plain>CD8(+) T cell responses to EBV lytic and latent antigens not expressed in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> were similarly robust in eBL patients compared to healthy children </plain></SENT>
<SENT sid="7" pm="."><plain>In addition, CD4(+) T cell responses to a <z:e sem="disease" ids="C0024530" disease_type="Disease or Syndrome" abbrv="">malaria</z:e> protein, merozoite surface protein 1, were present in <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients </plain></SENT>
<SENT sid="8" pm="."><plain>This study demonstrates a selective loss of EBNA1-specific T cell responses in children with eBL and suggests a potential immunotherapeutic target for this EBV-associated <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>